EmblemHealth, a US-based non-profit health insurer, has cut the number of medical procedures for which members will require prior authorisation before receiving care, effective 1 January 2020, it was reported yesterday.
The change affects all of the company's health insurance plans, including Medicaid managed care, Medicare Advantage, coverage provided through employers, and Individual Market plans on the Exchange.
Karen Ignagni, president and CEO of EmblemHealth, said, 'EmblemHealth is transforming all of its operations. As part of that effort, we are reducing red tape and simplifying administrative processes for our clinical partners. This has led us to cut prior authorisation requirements in half. Through careful analysis of our data, we identified services that almost always get approved. Not requiring prior authorisation of those services, such as surgical procedures where patients are going to the hospital (ie some cardiac and vascular procedures, gallbladder removal and treatment of glaucoma), will ensure that our members are receiving the care they need quickly and efficiently. Looking forward, we will continue to review our data with the goal of finding additional ways to reduce red tape and simplify administrative procedures.'
Viatris' generic iron sucrose injection gains US FDA approval
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
US FDA approves Innovent's IND application for IBI3032 oral GLP-1R agonist
GEN and Sulfateq report positive Phase 1 data for SUL-238 in Alzheimer's
Philips launches ECG AI Marketplace to streamline cardiac diagnostics
AstraZeneca's Baxdrostat meets all endpoints in pivotal Phase III hypertension trial
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
EDX Medical and Spire Healthcare sign strategic diagnostic partnership agreement
Bayer and Broad Institute extend cardiovascular research alliance to advance precision therapies